- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.04. | Aligos and Xiamen Amoytop sign deal for HBV therapy | ||
| 17.04. | Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions | ||
| 16.04. | Developers back Alzheimer's drugs despite report suggesting lack of efficacy | ||
| 16.04. | Lilly debuts more Foundayo data as FDA requests post-marketing trials | ||
| 16.04. | Terremoto wins $108m in Series C to drive cancer and rare disease programmes | ||
| 16.04. | Nucleai and Sirona Dx to provide new proteomics solution for pharma companies | ||
| 16.04. | Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study | ||
| 15.04. | FDA shares guide on genome editing best practices | ||
| 15.04. | Amazon launches AI drug discovery platform | ||
| 15.04. | J&J sets the tone for Q1 earnings with strong oncology growth | ||
| 15.04. | Adcendo secures $75m in Series C funding for ADC development | ||
| 15.04. | Lilly to acquire CrossBridge Bio for up to $300m | ||
| 14.04. | EU sees 2025 pharma export uptick amid competitiveness concerns | ||
| 14.04. | Pharma 5.0, Sustainability & Security: PHARMAP 2026 brings pharma's future into focus | ||
| 14.04. | Travere Therapeutics gains FDA approval for sparsentan in FSGS | ||
| 14.04. | Novo Nordisk and OpenAI forge alliance to drive speedy drug development | ||
| 14.04. | MSD, Daiichi Sankyo's ifinatamab deruxtecan receives FDA priority | ||
| 13.04. | AbbVie bets on Chinese biopharma's pain pipeline in $745m bid | ||
| 13.04. | Telix and Regeneron to co-develop radiopharmaceutical therapies | ||
| 13.04. | FDA issues complete response letter to Replimune's RP1 for melanoma | ||
| 10.04. | BMS and Oxford BioTherapeutics join forces in TCE discovery pact | ||
| 10.04. | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | ||
| 10.04. | Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation | ||
| 09.04. | EverSea Medicines to acquire Hasten Biopharmaceuticals | ||
| 09.04. | FDA seeks permanent future for rare pediatric priority review vouchers |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.